Citigroup Inc. Purchases 39,477 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Posted by Defense World Staff on Sep 5th, 2023

Citigroup Inc. grew its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 42.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 132,091 shares of the biotechnology company’s stock after buying an additional 39,477 shares during the quarter. Citigroup Inc. owned approximately 0.50% of Arcturus Therapeutics worth $3,166,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA grew its stake in Arcturus Therapeutics by 63.4% during the second quarter. BNP Paribas Arbitrage SA now owns 5,043 shares of the biotechnology company’s stock worth $79,000 after buying an additional 1,956 shares during the last quarter. Point72 Middle East FZE bought a new stake in shares of Arcturus Therapeutics during the fourth quarter valued at approximately $79,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Arcturus Therapeutics by 18.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,793 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 882 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in shares of Arcturus Therapeutics by 23.8% during the first quarter. Daiwa Securities Group Inc. now owns 4,109 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 789 shares during the last quarter. Finally, Point72 Hong Kong Ltd grew its stake in shares of Arcturus Therapeutics by 3,653.2% during the second quarter. Point72 Hong Kong Ltd now owns 6,493 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 6,320 shares during the last quarter. 88.87% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, COO Pad Chivukula sold 5,000 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $28.75, for a total transaction of $143,750.00. Following the sale, the chief operating officer now directly owns 544,448 shares in the company, valued at $15,652,880. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, insider Keith C. Kummerfeld sold 6,968 shares of the firm’s stock in a transaction on Friday, July 14th. The shares were sold at an average price of $35.00, for a total transaction of $243,880.00. Following the sale, the insider now directly owns 950 shares in the company, valued at $33,250. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Pad Chivukula sold 5,000 shares of the firm’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $28.75, for a total transaction of $143,750.00. Following the sale, the chief operating officer now owns 544,448 shares in the company, valued at $15,652,880. The disclosure for this sale can be found here. Insiders have sold a total of 36,968 shares of company stock worth $1,262,880 over the last ninety days. Company insiders own 13.80% of the company’s stock.

Arcturus Therapeutics Stock Performance

ARCT opened at $31.74 on Tuesday. The firm’s fifty day moving average is $31.31 and its two-hundred day moving average is $26.35. The firm has a market cap of $844.28 million, a PE ratio of 10.98 and a beta of 2.64. Arcturus Therapeutics Holdings Inc. has a twelve month low of $13.02 and a twelve month high of $37.75.

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($1.98) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($2.07). The firm had revenue of $10.52 million during the quarter, compared to analyst estimates of $71.05 million. Arcturus Therapeutics had a return on equity of 20.75% and a net margin of 30.36%. Equities analysts forecast that Arcturus Therapeutics Holdings Inc. will post -3.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ARCT shares. HC Wainwright reissued a “buy” rating and set a $51.00 price target on shares of Arcturus Therapeutics in a research note on Tuesday, August 15th. StockNews.com started coverage on shares of Arcturus Therapeutics in a research note on Thursday, August 17th. They set a “hold” rating on the stock. Wells Fargo & Company raised their price objective on shares of Arcturus Therapeutics from $35.00 to $45.00 in a research note on Monday, July 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $54.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, August 22nd. Finally, William Blair started coverage on shares of Arcturus Therapeutics in a research note on Monday, July 24th. They issued an “outperform” rating and a $71.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Arcturus Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $38.78.

View Our Latest Stock Analysis on Arcturus Therapeutics

Arcturus Therapeutics Company Profile

(Free Report)

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.